Biosimilars are saving money but not in the U.S., where companies have used a variety of stalling tactics. Now Pfizer and others are accusing Johnson & Johnson of withholding rebates to fend off biosimilar competition to Remicade.
Thomas Reinke
The TNF-α blocker is the world’s top-selling drug, by revenue. It faces biosimilar competition in Europe, but it will be four years before it’s challenged in the U.S.
Susan Ladika
The price of biologics can ruin cancer patients financially, this leading oncology expert reminds us. Biosimilars may help, but we need more of them on the market.
Interview by Peter Wehrwein

16 FDA-approved Biosimilars

Shaded rows indicate products on the market as of Jan. 14, 2019

  1. Herzuma (trastuzumab-pkrb, Celltrion and Teva)
  2. Truxima (rituximab-abbs, Celltrion)
  3. Udenyca (pegfilgrastim-cbqv, Coherus BioSciences)
  4. Hyrimoz (adalimumab-adaz, Sandoz)
  5. Nivestym (filgrastim-aafi, Pfizer)
  6. Fulphila (pegfilgrastim-jmdb, Mylan)
  7. Retacrit (epoetin alfa-epbx, Hospira*)
  8. Ixifi (infliximab-qbtx, Pfizer)
  9. Ogivri (trastuzumab-dkst, Mylan)
  10. Mvasi (bevacizumab-awwb, Amgen)
  11. Cyltezo (adalimumab-adbm, Boehringer Ingelheim)
  12. Renflexis (infliximab-abda, Merck)
  13. Amjevita (adalimumab-atto, Amgen)
  14. Erelzi (etanercept-szzs, Sandoz)
  15. Inflectra (infliximab-dyyb, Celltrion and Pfizer)
  16. Zarxio (filgrastim-sndz, Sandoz)

*Hospira is a subsidiary of Pfizer.

Complete list, with indications

Biosimilar News Wire

Phase 3 Study Confirmed Drug’s Comparable Safety and Efficacy
April 30, 2019
New Biosimilar Provides Broader Treatment Options for Patients
December 18, 2018
European study concludes clinicians can safely switch patients from originators to biosimilars
October 2, 2018
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
July 10, 2018
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.
July 10, 2018
They are ‘living’ molecules, and there is variability among lots, even in the reference products. The key issue is whether the variability has any clinical significance. So far, it hasn’t.
Thomas Reinke
The global biosimilar market is expected to be worth $36 billion by 2022,  according to a report issued by consultant Netscribes. The global market intelligence and content management firm takes a close look at the market favorability for biosimilars across developed, BRIC (Brazil, Russia, India and…